Study of Azacitidine and Durvalumab in Advanced Solid Tumours

Official Title

An Open-label, Phase II Basket Study of a hypoMEThylating Agent Oral Azacitidine and DURvalumab (MEDI4736) (Anti-PDL1) in Advanced Solid Tumours (METADUR)


This is a phase 2 study of investigational drug, durvalumab given in combination with azacitidine (CC-486). The main purpose of this phase 2 study is to assess the antitumour activity of azacitidine in combination with durvalumab patients with microsatellite stable colorectal carcinoma (MSS-CRC), platinum resistant epithelial ovarian cancer type II (PR-OC), and estrogen receptor positive and HER2 negative breast cancer.

Trial Description

Primary Outcome:

  • Overall response rate (ORR)
Secondary Outcome:
  • Disease Control Rate (DCR)
  • Progression-free survival (PFS)
  • Overall survival (OS)
  • Incidence of treatment-emergent adverse events (AEs)

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society